Neumora Therapeutics, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 68/100
What the filing says
On June 10, 2026, Neumora Therapeutics amended its Loan and Security Agreement with K2 HealthVentures LLC. Key changes: (1) relaxed financial covenant from 105% to 110% of total senior debt obligations; (2) extended amortization commencement date to May 1, 2029; (3) paid a non-refundable amendment fee of $445,000. The company also released all prior claims against lenders. Specific dollar amounts and share counts beyond the $445K fee are redacted as confidential.
Why this rating
Covenant relaxation and fee ($445K ≈ 0.7% of market cap) signal cash stress; extension buys time but indicates liquidity pressure. Material for a $63M company.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.